menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Mitigating Risk in New IBD Treatments– IBD Pro Webinar Series

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    • How to Mitigate Risks in New Therapies – IBD Pro Webinar Series Jointly provided by Postgraduate Institute for Medicine and Crohn’s & Colitis Foundation
    • If applicable: This activity is supported by an independent educational grant from Takeda Pharmaceuticals
    • Release date: Sept 6, 2023
    • Expiration date: Sept 6, 2024
    • Estimated time to complete activity: 1 hour
  • Target Audience

    This activity is intended for physicians, APPs, Nurses, pharmacists and multi-disciplinary team members who are engaged in the care of patients with inflammatory bowel disease (IBD) in primary care, managed care organizations, ambulatory care, and hospital settings.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    • Discuss treatments for patients with IBD, taking into consideration disease history, disease severity, and patient preference
    • Demonstrate shared decision-making and co-production models that facilitate open provider/patient dialogue
    • Optimize communication methods and empower patients
    • Recognize the impact of IBD on patients and
    • Apply evidence-based IBD pathways in patient education and shared decision-making
    • Implement co-productive patient-provider strategies including key learnings from clinical trial results and emerging research in IBD into clinical practice to improve overall patient outcomes
    • Identify areas of miscommunication and engage patients on management expectations for Crohn’s and UC

  • Faculty

    Parrakal Deepak, MBBS, MS 

    Preetika Sinh, MD

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

    ParrakalDeepak, MBBS, MS - Disclosures

    Consultant or on an advisory board for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Bristol Myers Squibb, Sandoz, Fresenius Kabi, CorEvitas LLC and Scipher Medicine Corporation. Funding under a sponsored research agreement from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb-Celgene, Abbvie, Janssen, Landos Pharmaceuticals, Direct Biologics, and Boehringer Ingelheim.

    Preetika Sinh, MD - No Disclosures

    The PIM planners and others have nothing to disclose. The Crohns & Colitis Foundation planners and others have nothing to disclose

  • Method of Participation and Request for Credit

    In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

    1. Go to www.cmeuniversity.com
    2. Login or Create a New Account (will take less than 1 minute)
      1. If you receive a message when creating a new account that “the email you entered is already in use”, please click the forgot my username or password link to have your Username and Password sent to you via email
      2. After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
    3. Type in 18165 at the top of the page, “Find Post-Test/Evaluation by Course”, and click enter
    4. Click on the activity title when it appears
    5. Choose the type of credit you desire
    6. (If applicable) Complete the Post-test with a passing score of 75% or better
    7. Complete the online Evaluation
    8. Receive an immediate CE Certificate to download and/or print for your files

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

  • Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Crohn’s & Colitis Foundation Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Nursing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. 

    Continuing Pharmacy Education
    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. 

    (Universal Activity Number - JA4008162-9999-23-338-H04-P)
    Type of Activity: Application 

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    • How to Mitigate Risks in New Therapies – IBD Pro Webinar Series Jointly provided by Postgraduate Institute for Medicine and Crohn’s & Colitis Foundation
    • If applicable: This activity is supported by an independent educational grant from Takeda Pharmaceuticals
    • Release date: Sept 6, 2023
    • Expiration date: Sept 6, 2024
    • Estimated time to complete activity: 1 hour
  • Target Audience

    This activity is intended for physicians, APPs, Nurses, pharmacists and multi-disciplinary team members who are engaged in the care of patients with inflammatory bowel disease (IBD) in primary care, managed care organizations, ambulatory care, and hospital settings.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    • Discuss treatments for patients with IBD, taking into consideration disease history, disease severity, and patient preference
    • Demonstrate shared decision-making and co-production models that facilitate open provider/patient dialogue
    • Optimize communication methods and empower patients
    • Recognize the impact of IBD on patients and
    • Apply evidence-based IBD pathways in patient education and shared decision-making
    • Implement co-productive patient-provider strategies including key learnings from clinical trial results and emerging research in IBD into clinical practice to improve overall patient outcomes
    • Identify areas of miscommunication and engage patients on management expectations for Crohn’s and UC

  • Faculty

    Parrakal Deepak, MBBS, MS 

    Preetika Sinh, MD

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

    ParrakalDeepak, MBBS, MS - Disclosures

    Consultant or on an advisory board for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Bristol Myers Squibb, Sandoz, Fresenius Kabi, CorEvitas LLC and Scipher Medicine Corporation. Funding under a sponsored research agreement from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb-Celgene, Abbvie, Janssen, Landos Pharmaceuticals, Direct Biologics, and Boehringer Ingelheim.

    Preetika Sinh, MD - No Disclosures

    The PIM planners and others have nothing to disclose. The Crohns & Colitis Foundation planners and others have nothing to disclose

  • Method of Participation and Request for Credit

    In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

    1. Go to www.cmeuniversity.com
    2. Login or Create a New Account (will take less than 1 minute)
      1. If you receive a message when creating a new account that “the email you entered is already in use”, please click the forgot my username or password link to have your Username and Password sent to you via email
      2. After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
    3. Type in 18165 at the top of the page, “Find Post-Test/Evaluation by Course”, and click enter
    4. Click on the activity title when it appears
    5. Choose the type of credit you desire
    6. (If applicable) Complete the Post-test with a passing score of 75% or better
    7. Complete the online Evaluation
    8. Receive an immediate CE Certificate to download and/or print for your files

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

    If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

  • Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Crohn’s & Colitis Foundation Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    Physician Continuing Medical Education
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Nursing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. 

    Continuing Pharmacy Education
    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. 

    (Universal Activity Number - JA4008162-9999-23-338-H04-P)
    Type of Activity: Application 

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Facebook Comments

Schedule18 Jul 2024